Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older and have been diagnosed with acute myeloid leukemia (AML) that has come back or stopped responding to available treatments
- You are able to carry out basic daily activities, with your overall health and activity level falling within an acceptable range as rated by your doctor (a score of 0, 1, or 2 on a standard scale)
- In the later part of the trial, you may be eligible if you have AML and your doctor considers you suitable for a specific chemotherapy medicine called decitabine
- Your liver is working well enough, shown by specific blood test results being within acceptable ranges (confirm with trial site)
- Your kidneys are working well enough, shown by your kidney filtering rate being at least 60 mL/min as calculated by your doctor (confirm with trial site)
- If you are a woman who could become pregnant, you must agree to use an accepted form of birth control throughout the study and for at least 6 months after your last dose
- If you are a man, you must agree to use an accepted form of contraception for the duration of the study
- You have fully recovered from any past surgery, radiation, or cancer treatment side effects (hair loss is an exception)
- You are willing and able to sign a written consent form agreeing to take part in the trial
Who may not be able to join:
- You have another active cancer (not a blood or lymph node cancer) that has been treated with cancer-fighting medicines or therapies in the past 12 months
- You have leukemia that has spread to the fluid around your brain or spinal cord and is currently being actively treated (confirm with trial site)
- Your leukemia is only found outside the bone marrow and does not also meet the bone marrow requirements for AML (confirm with trial site)
- You have a specific type of leukemia called acute promyelocytic leukemia (APL) with a particular genetic change
- You have chronic myeloid leukemia (CML) at any stage
- You have received any cancer treatment within 14 days before starting the trial, with limited exceptions such as a medicine called hydroxyurea or a blood-filtering procedure
- You are currently taking part in another clinical trial involving an experimental treatment
- You are pregnant or breastfeeding
- You have substance use, medical, mental health, or social issues that could affect your ability to take part in or complete the study
- You have HIV with a low immune cell count, or you have an active hepatitis B or C infection
- You have had a previous allergic reaction to a type of cancer medicine called a hypomethylating agent (confirm with trial site)
- You still have unresolved side effects from a previous treatment that are above a mild level (hair loss is an exception)
- You have serious heart conditions, such as severe heart failure, uncontrolled high blood pressure, a significant irregular heartbeat, or an abnormal heart reading on an ECG
- In the past 6 months, you have had a heart attack, unstable chest pain, heart or artery bypass surgery, a stroke, or a mini-stroke
- You have had seizures within the past 2 months that are not controlled
- You are unwilling or unable to communicate with the study team or follow the study rules for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gail J Roboz, MD, Weill Cornell Medical College - New York-Presbyterian Hospital
Phone: 832-742-1361
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identify Dose Limiting Toxicity (DLT) of BP1002; Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002; Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002; Recommended Phase 2 (RP2D) of BP1002; Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration; Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution; Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant; Determine half-life plasma pharmacokinetics (PK) of BP1002; Identify conducti...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.